Indegene Ltd

Indegene Ltd, a key player in the healthcare services sector, has touched a new 52-week low of Rs.463, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and broader market indices, reflecting ongoing pressures on its valuation and performance metrics.

Indegene Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 January 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 24 January 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Indegene Ltd, a key player in the Healthcare Services sector, touched a fresh 52-week low of Rs.471.45 today, marking a significant decline in its stock price amid a backdrop of subdued financial results and extended underperformance relative to market benchmarks.

Indegene Ltd, a key player in the healthcare services sector, recorded a fresh 52-week low of Rs.483 on 19 Jan 2026, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and broader market indices, reflecting a challenging period for the company’s share price.

Indegene Ltd, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, with bearish trends intensifying despite some bullish signals on shorter-term indicators. The stock’s recent downgrade from a Sell to a Hold rating by MarketsMOJO reflects this nuanced technical landscape, as investors weigh the implications of weakening price momentum against pockets of resilience.

Indegene Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Indegene Ltd, a key player in the Healthcare Services sector, has experienced a nuanced shift in its technical momentum as of early January 2026. While the stock price edged up modestly to ₹522.20, technical indicators reveal a complex picture with mixed signals across weekly, monthly, and daily timeframes, prompting a downgrade in its Mojo Grade from Hold to Sell on 29 December 2025.

Indegene Ltd, a key player in the Healthcare Services sector, has seen its investment rating downgraded from Hold to Sell as of 29 Dec 2025. This adjustment reflects a combination of deteriorating technical indicators, flat recent financial performance, and underwhelming stock returns compared to benchmarks, despite some positive fundamentals such as strong management efficiency and low debt levels.

Indegene, a key player in the healthcare services sector, has experienced a notable shift in its technical momentum as recent market data reveals a complex interplay of bearish and bullish signals. The stock’s price movement, combined with technical indicators such as MACD, RSI, and moving averages, suggests a nuanced market assessment amid broader sector dynamics.

Indegene Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Indegene, a key player in the Healthcare Services sector, has exhibited notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition in price trends and technical indicators, underscoring a nuanced market assessment for the stock as it navigates current trading conditions.

Indegene, a key player in the healthcare services sector, has recently experienced a shift in market evaluation driven by a combination of financial performance, valuation metrics, and technical indicators. This article analyses the factors influencing the current market perspective on Indegene, highlighting the interplay between its operational results, stock price movements, and broader market trends.

Indegene, a key player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, reflecting a more cautious market stance. Recent evaluation adjustments highlight a transition towards bearish signals across several technical indicators, coinciding with subdued price performance relative to benchmark indices.

Indegene, a small-cap player in the Healthcare Services sector, has experienced a revision in its market evaluation, reflecting nuanced shifts across key analytical parameters. This change highlights evolving perspectives on the company’s financial health, valuation, and technical outlook amid a challenging market environment.

Indegene, a key player in the Healthcare Services sector, has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent market data reveals a subtle change in the stock’s price dynamics, with technical indicators such as MACD, RSI, and moving averages offering a mixed perspective on its near-term trajectory.

Indegene, a key player in the Healthcare Services sector, is currently exhibiting a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and bullish signals across multiple timeframes. Recent evaluation adjustments highlight a transition in market assessment, with technical indicators such as MACD, RSI, and moving averages providing a mixed outlook for investors navigating this small-cap stock.

Indegene, a key player in the Healthcare Services sector, has undergone a revision in its market evaluation following a detailed analysis of its quality, valuation, financial trends, and technical indicators. Despite flat quarterly financial results and subdued stock returns over the past year, shifts in technical patterns and institutional interest have influenced the overall market perspective on the company.